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Overview of the Burden of Diabetes 
Diabetes is the nation’s seventh leading cause of death. The National Diabetes Statistics Report, 2020 
estimates that 34.2 million Americans of all ages have diabetes. This is approximately 10.5% of the 
entire United States population. More specifically, 34.1 million adults aged 18 years or older have 
diabetes. This is approximately 13% of all adults in the United States. The report also found that newer 
cases were identified more frequently in non-Hispanic blacks and people of Hispanic origin rather than 
non-Hispanic Asians and non-Hispanic whites1. In New Hampshire, 10.3% of adults had diabetes in 
20192. Diabetes is becoming one of the most expensive chronic diseases in the nation, costing the 
United States $327 billion in 20173. Based on the estimated national cost of diabetes, $237 billion 
(about 73%) represents direct health care expenditures attributed to diabetes, whereas $90 billion 
(about 27%) represents lost productivity3. The excess costs associated with medications represents 
43% of total direct medical burden – $15 billion for insulin, $15.9 billion for other anti-diabetes agents, 
and $71.2 billion in prescription medication use attributed to comorbidities frequently associated with 
diabetes3. Before rebates or discounts, insulin accounts for $48 billion, or about 20% of the direct costs 
in treating diabetes. The average listing price of insulin, between the years 2001 to 2018, has increased 
11% annually4. 
                                                          
1 Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease 
Control and Prevention, U.S. Dept of Health and Human Services; 2020. Retrieved October 29, 2020 from 
https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf 
2 America's Health Rankings. Diabetes in NH Annual Report. United Health Foundation, Retrieved October 29, 2020, from 
https://www.americashealthrankings.org/explore/annual/measure/Diabetes/state/NH?edition-year=2019 
3 American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. (2018, March). Diabetes Care, 41(5), 917-
928. doi: 10.2337/dci18-0007. 
4 Hayes, T. O., & Farmer, J. (2020, April 02). Insulin Cost and Pricing Trends. Retrieved October 29, 2020, from 
https://www.americanactionforum.org/research/insulin-cost-and-pricing-trends/  
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Overview of NH Claims Analysis 
This report includes data and visualizations from the NH Claims Report Suite 
(https://chhs.unh.edu/institute-health-policy-practice/focal-areas/health-analytics-informatics) that 
describe medical and pharmaceutical costs for diabetes in NH’s commercial, Medicaid, and Medicare 
populations.  Pharmacy and medical costs are estimated separately throughout this report. 
The regulations that establish the NH Comprehensive Healthcare Information System (NH CHIS) 
(https://nhchis.com/) require that commercial insurers submit claims and enrollment data to the NH 
Department of Health and Human Services on a monthly basis. Some NH licensed insurers fall below 
the threshold of 10,000 covered lives and are not required to submit data to NH CHIS, and therefore 
are not included in this analysis. Based on availability and quality of the data, the analysis for this 
report is limited to the top commercial medical insurers (Cigna, Anthem, Harvard Pilgrim, Tufts, Health 
Plans Inc., Matthew Thornton, and Tufts Health Freedom) and the top commercial pharmacy insurers 
(Harvard Pilgrim, Tufts, Tufts Health Freedom, Caremark, Matthew Thornton, and Express Scripts). 
These insurers contribute more than 80% of the commercial medical and pharmacy claims data in a 
typical year.5  
NH Medicaid data is limited to enrollment and claims from the Medicaid managed care organizations 
(NH Healthy Families, Well Sense and AmeriHealth) and Medicaid Fee-For-Service. Premium Assistance 
Plan (i.e. the Medicaid Expansion program) enrollment and claims data are not included.  
The NH Medicare medical data includes members who are enrolled in both Medicare Parts A and B. 
The NH Medicare pharmacy data includes members who are enrolled in Medicare Part D. Medicare 
Advantage plans are not included in the analysis. 
  
                                                          
5 In March 2016, the Supreme Court ruled that Liberty Mutual, as a self-insured employer, can choose not to submit their 
health claims data to Vermont's all-payer claims database. This decision resulted in many commercial insurers opting not to 
submit the self-insured business to the NH CHIS. Therefore, please use caution in interpreting analysis/measures derived 
from data after March2016, because there are fewer employer plans submitting data after March 2016. For information 
about the Supreme Court decision, please see https://www.supremecourt.gov/opinions/15pdf/14-181_5426.pdf. 
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A summary of the number of covered lives by data source and analytic period is presented in Table 1. 
Table 1: Number of Covered Lives for Commercial, Medicaid and Medicare by Claims Type and Analytic Period 
Data 
Source Claims Type 
Population 







Medical 0-64 7/1/2017 to 6/30/2018 7/1/2018 to 6/30/2019 569,556 550,195 
Pharmacy 0-64 7/1/2017 to 6/30/2018 7/1/2018 to 6/30/2019 773,118 793,245 
Medicaid 
Medical 0-64 1/1/2018 to 12/31/2018 1/1/2019 to 12/31/2019 191,098 217,995 
Pharmacy 0-64 1/1/2018 to 12/31/2018 1/1/2019 to 12/31/2019 191,098 217,995 
Medicare 
Medical All ages 1/1/2017 to 12/31/2017 1/1/2018 to 12/31/2018 233,982 234,510 
Pharmacy All ages 1/1/2017 to 12/31/2017 1/1/2018 to 12/31/2018 196,960 205,500 
 
For more information about data included in this analysis, please see Appendix A. The analytic periods 
vary among commercial, Medicaid, and Medicare data because the data is received on different 
schedules from the various data sources. For more information about additional data and reports 
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Percent of Insured Population Impacted by Diabetes 
The “percentage of member months” can be used as a proxy for understanding the percentage of the 
insured population that has received treatment for a disease or condition. The use of “member 
months” accounts for the incomplete years of coverage for individual members. For the purposes of 
this analysis, the top 20 conditions by member months are presented in Tables 2-4 to allow for 
comparison of diabetes and related conditions. The conditions are associated to an Episode Treatment 
Group (ETG) as defined by OPTUMInsight’s Symmetry Episode Treatment Groups®.  Note: The lists of 
ETGs presented in this report include conditions, as well as service categories that are not associated 
with a specific clinical condition (e.g. “routine exam”). 
For the purpose of this report, the following conditions are highlighted in the tables below: Congestive 
Health Failure (CHF), Diabetes, Hypertension, and Cardiovascular Disease (CVD). 
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While hypertension ranks second in this list, it is the highest ranked clinical condition with 15.30% of 
the total member months in the NH commercial population included in the NH CHIS analysis in FY 2018 
(Table 2). Diabetes is ranked 16th with 6.57% of total member months in the NH commercial population 
in FY 2018. CVD and CHF were not in the top 20 list of conditions in terms of the percentage of total 
member months, with these conditions ranking 43rd (2.49%) and 113th (.99%) respectively. 
Table 2: Top 20 Episode Treatment Groups Ranked by Percent of Member Months from July 1, 2018 to June 30, 2019 for 
the NH Commercial Data 
 
Episode Treatment Group (ETG) 










1 Routine exam 41.35% 42.84% 
2 Hypertension 15.25% 15.30% 
3 Screenings & immunizations incidental to other services - immunizations 11.45% 12.36% 
4 Non-routine inoculation 8.67% 9.79% 
5 Visual disturbances 7.99% 8.07% 
6 Non-malignant neoplasm of skin 7.54% 8.02% 
7 Tonsillitis, adenoiditis or pharyngitis 7.77% 7.99% 
8 Mood disorder, depressed 7.16% 7.34% 
9 Other inflammation of skin 6.86% 7.13% 
10 Isolated signs, symptoms & non-specific diagnoses or conditions 6.98% 7.09% 
11 Other disorders of ear/nose/throat 6.65% 7.03% 
12 Joint degeneration, localized - back 6.90% 6.82% 
13 Obesity 6.54% 6.81% 
14 Conditional exam 6.21% 6.76% 
15 Anxiety disorder or phobias 6.27% 6.59% 
16 Diabetes 6.62% 6.57% 
17 Cataract 6.48% 6.28% 
18 Hyperlipidemia, other 5.86% 5.92% 
19 Screenings & immunizations incidental to other services - mammogram 5.58% 5.63% 
20 Hypo-functioning thyroid gland 5.20% 5.27% 
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NH Medicaid 
Hypertension ranks eighteenth with 5.61% of member months with hypertension in the NH Medicaid 
population in 2019 (Table 3). Diabetes is not in the top 20 list of conditions in terms of the percentage 
of total member months with diabetes in the NH Medicaid population; it ranks 26th with 3.46% of the 
member months with diabetes. Likewise, CVD and CHF were also not in the top 20 list of conditions, 
ranking 38th (2.42%) and 149th (.56%) respectively. 
Table 3: Top 20 Episode Treatment Groups Ranked by Percent of Member Months from January 1, 2019 to December 31, 
2019 for the NH Medicaid Population 
 
Episode Treatment Group (ETG) 










1 Routine exam 46.71% 43.48% 
2 Tonsillitis, adenoiditis or pharyngitis 15.12% 13.40% 
3 Visual disturbances 13.41% 12.39% 
4 Mood disorder, depressed 9.60% 10.44% 
5 Non-routine inoculation 8.73% 9.81% 
6 Otitis media 10.37% 8.64% 
7 Isolated signs, symptoms & non-specific diagnoses or conditions 7.35% 7.49% 
8 Other drug dependence 6.30% 7.44% 
9 Other neuropsychological or behavioral disorders 7.82% 7.28% 
10 Asthma 8.00% 7.25% 
11 Development disorder 9.69% 6.98% 
12 Anxiety disorder or phobias 6.05% 6.76% 
13 Otolaryngology diseases signs & symptoms 7.35% 6.56% 
14 Screenings & immunizations incidental to other services - immunizations 6.77% 6.48% 
15 Gastroenterology diseases signs & symptoms 5.79% 6.09% 
16 Other inflammation of skin 6.13% 5.94% 
17 Opioid or barbiturate dependence 4.54% 5.64% 
18 Hypertension 4.66% 5.61% 
19 Obesity 5.11% 5.38% 
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Hypertension ranks first with 46.45% of the total member months with hypertension in the NH 
Medicare population in 2018 (Table 4). Diabetes is ranked 6th with 20.98% of total member months 
with diabetes in the NH commercial population in 2018. CVD and CHF were not in the top 20 list of 
conditions in terms of the percentage of total member months, with these conditions ranked 74th 
(2.41%) and 30th (6.63%) respectively. 
Table 4: Top 20 Episode Treatment Groups Ranked by Percent of Member Months from January 1, 2018 to December 31, 
2018 for the NH Medicare Population 
 
Episode Treatment Group (ETG) 










1 Hypertension 46.39% 46.45% 
2 Screenings & immunizations incidental to other services - immunizations 32.57% 33.74% 
3 Routine exam 26.24% 28.01% 
4 Cataract 27.90% 27.55% 
5 Hyperlipidemia, other 22.75% 22.44% 
6 Diabetes 21.36% 20.98% 
7 Joint degeneration, localized - back 16.94% 16.36% 
8 Hypo-functioning thyroid gland 14.64% 14.74% 
9 Ischemic heart disease 14.75% 14.65% 
10 Non-routine inoculation 15.27% 14.42% 
11 Conditional exam 12.62% 13.34% 
12 Non-malignant neoplasm of skin 12.21% 13.19% 
13 Obesity 12.95% 12.88% 
14 Other disorders of ear/nose/throat 12.10% 12.34% 
15 Glaucoma 11.59% 11.69% 
16 Joint degeneration, localized - knee & lower leg 11.17% 11.20% 
17 Screenings & immunizations incidental to other services - mammogram 11.57% 10.80% 
18 Chronic obstructive pulmonary disease 11.36% 10.69% 
19 Mood disorder, depressed 10.88% 10.68% 
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Medical Costs for Diabetes and Selected Chronic Conditions 
The total medical cost for members who have one or more selected chronic conditions (Asthma, 
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes, Hypertension, 
Cardiovascular Disease, Mood Disorder-Depressed, Mood Disorder-Bipolar, and Anxiety 
Disorder/Phobia)6 is presented for NH commercial, Medicaid, and Medicare populations during the 
periods of FY 2017 and FY 2018. Pharmaceutical costs are not included in the estimates of medical 
costs for these conditions.  
  
                                                          
6 Note: OPTUMInsight’s Symmetry Episode Treatment Groups® (ETGs®) was used to identify the following representative 
chronic conditions in the report: Asthma, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes, 
Hypertension, Cardiovascular Disease, Mood Disorder-Depressed, Mood Disorder-Bipolar and Anxiety Disorder/Phobia. 
Please see OPTUMInsight for additional information on ETGs®.  “Comorbidity” refers to comorbidity with Asthma, 
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes, Hypertension, Cardiovascular Disease, Mood 
Disorder-Depressed, Mood Disorder-Bipolar or Anxiety Disorder/Phobia. 
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NH Commercial 
In the commercial population included in the NH CHIS data analysis, the medical costs for members 
with diabetes grew slightly between FY 2017 and FY 2018 from $273.3 million to $283.1 million, 
respectively (see Table 5). In both FY 2017 and FY 2018, a large proportion of all costs for members 
with diabetes was for members with diabetes and a co-morbidity ($250.4M and $259.0M respectively).  
In comparison with other chronic conditions, the costs for treatment of diabetes are greater than the 
current period costs for CVD ($186.2M) and CHF ($109.3M). The medical costs of hypertension are 
almost three times that of costs for members with diabetes. 
Table 5: Medical Cost for Diabetes, Hypertension, CVD, and CHF by Comorbidity Status for the NH Commercial Data 
Chronic Condition Comorbidity  Indication Level 
Medical Cost (allowed) 
7/1/2017 to 6/30/2018 
in Millions 
Medical Cost (allowed) 
7/1/2018 to 6/30/2019 
in Millions 
Diabetes All $273.3M  $283.1M  
Diabetes Without Comorbidity $22.8M  $24.1M  
Diabetes With Comorbidity $250.4M  $259.0M  
Hypertension All $719.2M  $738.3M  
Hypertension Without Comorbidity $183.0M  $187.1M  
Hypertension With Comorbidity $536.3M  $551.2M  
CVD (Cardiovascular Disease) All $177.9M  $186.2M  
CVD (Cardiovascular Disease) Without Comorbidity $8.7M  $10.0M  
CVD (Cardiovascular Disease) With Comorbidity $169.3M  $176.3M  
CHF (Congestive Heart Failure) All $102.6M  $109.3M  
CHF (Congestive Heart Failure) Without Comorbidity $6.5M  $5.7M  
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The pattern in medical costs for the NH Medicaid population is similar to that of commercial data in 
that the members with diabetes and a co-morbidity are a large proportion of the medical cost for all 
members with diabetes (see Table 6). In 2019, the total medical cost of treatment for members with 
diabetes ($134.1M) was less than the total medical costs for members with hypertension ($232.9M) 
and greater than the total medical cost for members with CHF ($39.1M) and CVD ($49.4M). 
Table 6: Medical Cost for Diabetes, Hypertension, CVD, and CHF by Comorbidity Status for the NH Medicaid Population 
Chronic Condition Comorbidity  Indication Level 
Medical Cost (allowed) 
1/1/2018 to 12/31/2018 
in Millions 
Medical Cost (allowed) 
1/1/2019 to 12/31/2019 
in Millions 
Diabetes All $112.7M  $134.1M  
Diabetes Without Comorbidity $12.3M  $15.3M  
Diabetes With Comorbidity $100.4M  $118.9M  
Hypertension All $190.3M  $232.9M  
Hypertension Without Comorbidity $34.1M  $38.3M  
Hypertension With Comorbidity $156.2M  $194.6M  
CVD (Cardiovascular Disease) All $42.8M  $49.4M  
CVD (Cardiovascular Disease) Without Comorbidity $2.3M $2.0M  
CVD (Cardiovascular Disease) With Comorbidity $40.6M  $47.4M  
CHF (Congestive Heart Failure) All $33.6M  $39.1M  
CHF (Congestive Heart Failure) Without Comorbidity $2.3M  $2.8M  
CHF (Congestive Heart Failure) With Comorbidity $31.3M  $36.3M  
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In the NH Medicare population, the medical costs grew slightly from CY 2017 to CY 2018 in that the 
costs for members with diabetes was $945.5 million and $983.2 million, respectively (see Table 7). In 
both CY 2017 and CY 2018, a large proportion of the costs for members with diabetes was for members 
with diabetes and a co-morbidity ($929.0M and $964.9M respectively).  
In comparison with other chronic conditions, the costs for treatment for members with diabetes are 
greater than the current period costs for treatment for members with CVD ($939.9M) and CHF 
($752.6M). The medical costs of treatment for members with hypertension are over twice that of costs 
for treatment for members with diabetes. 
Table 7: Medical Cost for Diabetes, Hypertension, CVD, and CHF by Comorbidity Status for the NH Medicare Population 
Chronic Condition Comorbidity  Indication Level 
Medical Cost (allowed) 
1/1/2017 to 12/31/2017 
in Millions 
Medical Cost (allowed) 
1/1/2018 to 12/31/2018 
in Millions 
Diabetes All $945.5M  $983.2M  
Diabetes Without Comorbidity $16.5M  $18.2M  
Diabetes With Comorbidity $929.0M  $964.9M  
Hypertension All $2,059.0M  $2,158.8M  
Hypertension Without Comorbidity $250.0M  $278.5M  
Hypertension With Comorbidity $1,809.1M  $1,880.3M  
CVD (Cardiovascular Disease) All $911.4M  $939.9M  
CVD (Cardiovascular Disease) Without Comorbidity $11.4M  $13.4M  
CVD (Cardiovascular Disease) With Comorbidity $900.1M  $926.5M 
CHF (Congestive Heart Failure) All $722.7M  $752.6M  
CHF (Congestive Heart Failure) Without Comorbidity $4.0M  $5.8M  
CHF (Congestive Heart Failure) With Comorbidity $718.7M  $746.8M  
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Summary of NH Medical Costs for Diabetes and Related Chronic Conditions 
In Figure 1 below, the three types of payers are presented side-by-side for each of the four conditions 
(diabetes, hypertension, CVD, and CHF) for both time periods. 
 
Figure 1: Costs per Condition (Diabetes, Hypertension, CVD, and CHF) by Payer by 12-Month Period 
Note: The cost estimates from the commercial data represent about half of the actual costs in the commercial 
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Pharmaceutical Treatment for Diabetes – Therapeutic Classes of Drugs 
Analysis of pharmacy claims can be done in a way to organize prescriptions into therapeutic classes, or 
groupings, of drugs. In this analysis, the Wolter Kluwer's UpToDate® software was used to identify the 
therapeutic class of antidiabetic agents and compare to other therapeutic classes of prescription 
drugs7. For an estimate of the number of prescriptions in each therapeutic class, this analysis 
estimated the number of prescriptions per 1000 prescriptions filled. For an estimate of the cost of the 
prescriptions by therapeutic class, this analysis estimated the cost per member per month. 
  
                                                          
7 ©2020 UpToDate, Inc. and/or its affiliates. All rights reserved 
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NH Commercial 
The antidiabetic drug class is the fifth largest class (see Figure 2) for the NH commercial data in NH 
CHIS in FY 2018. 
 
Figure 2: Refills per 1,000 Members for the Top 10 Drug Classes (Ranked by Total Scripts) from July 1, 2018 to June 30, 
2019 for the NH Commercial Data 
 
Antidiabetic drugs make up 5.7% of the member months with a prescription in the analytic period, 
representing 551 prescriptions per 1000 members (see Table 8) and a total cost of $102.9 million.  This 
means that approximately 6% of the commercial population had at least one prescription fill for an 
antidiabetic drug. 
Table 8: Antidiabetic Agents from July 1, 2018 to June 30, 2019 for the NH Commercial Data 
Drug Class 
% of Member 






Rx per 1,000 
7/1/2018 to 
6/30/2019 
Cost per Rx 
7/1/2018 to 
6/30/2019 
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Among the ten most commonly filled drug classes in the commercial population, the antidiabetic drug 
class is, by far, the most expensive for the members with those prescriptions (Figure 3). For this 
population, the NH CHIS data analysis demonstrates a cost of $348.78 per member per month (Table 
8). 
 
Figure 3: PMPM Class Cost for Class Members for the Top 10 Drug Classes (Ranked by Total Scripts) from July 1, 2018 to 
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NH Medicaid 
The antidiabetic drug class is the 8th largest class (see Figure 4) for the NH Medicaid population in 2019.  
 
Figure 4: Refills per 1,000 Members for the Top 10 Drug Classes (Ranked by Total Scripts) from January 1, 2019 to 
December 31, 2019 for the NH Medicaid Population 
 
Antidiabetic drugs represent 2.86% of the member months with a prescription in the analytic period, 
which makes up 321 prescriptions per 1000 members (see Table 9) and a total cost of $15.4 million in 
2019 for NH Medicaid.  
Table 9: Antidiabetic Agents from January 1, 2019 to December 31, 2019 for the NH Medicaid Population 
Drug Class 
% of Member 






Rx per 1,000 
1/1/2019 to 
12/31/2019 
Cost per Rx 
1/1/2019 to 
12/31/2019 
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The antidiabetic drug class is the most expensive per member per month for the NH Medicaid 
population at $272.20 per member per month for those that had a prescription in the antidiabetic drug 
class (Figure 5). 
 
Figure 5: PMPM Class Cost for Class Members for the Top 10 Drug Classes (Ranked by Total Scripts) from January 1, 2019 
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NH Medicare 
The antidiabetic drug class is the sixth largest class of prescriptions per 1,000 (see Figure 6) for the NH 
Medicare population in 2018. 
 
Figure 6: Refills per 1,000 Members for the Top 10 Drug Classes (Ranked by Total Scripts) from January 1, 2018 to 
December 31, 2018 for the NH Medicare Population 
 
Antidiabetic drugs represent 16.96% of the member months with a prescription in the analytic period, 
which makes up 1,492 prescriptions per 1000 members (see Table 10) and a total cost of $90.7 million 
in 2018 for NH Medicare.  
Table 10: Antidiabetic Agents from January 1, 2018 to December 31, 2018 for the NH Medicare Population 
Drug Class 
% of Member 






Rx per 1,000 
1/1/2018 to 
12/31/2018 
Cost per Rx 
1/1/2018 to 
12/31/2018 
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For members in the NH Medicare population with an antidiabetic drug prescription, the antidiabetic 
drug class is the most expensive per member per month (Figure 7) at $313.74 (Table 8). 
 
Figure 7: PMPM Class Cost for Class Members for the Top 10 Drug Classes (Ranked by Total Scripts) from January 1, 2018 
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Pharmaceutical Treatment for Diabetes – Drugs by National Drug Code 
The pharmaceutical claims analysis by individual drugs is conducted at the level of National Drug Code8 
(NDC). The analysis subsets the pharmacy data and uses the top 200 drugs by allowed cost for the 
entire population per analytic period. The analysis in this report provides PMPMs for the top 10 (of the 
Top 200) NDCs as ranked by allowed cost.  
  
                                                          
8 Wolter Kluwer's UpToDate® software was used to identify National Drug Codes. © 2020 UpToDate, Inc. and/or its 
affiliates. All rights reserved. 
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NH Commercial 
Victoza, Trulicity Pen, and the Lantus Solostar Pen are drugs used in the treatment of diabetes and are 
in the top 10 most expensive drugs in NH Commercial data in NH CHIS in FY 2018.  
 
 
Figure 8: Top 10 NDCs by Allowed Cost of the Top 200 NDCs (by Allowed Cost for Entire Population), Ordered by PMPM 
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NH Medicaid 
There are no antidiabetic drugs in the top 10 most expensive drugs in NH Medicaid in 2019.  
 
Figure 9: Top 10 NDCs by Allowed Cost of the Top 200 NDCs (by Allowed Cost for Entire Population), Ordered by PMPM 
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NH Medicare 
Lantus Solostar Pen is in the top 10 most expensive drugs in NH Medicare in 2018.  
 
Figure 10: Top 10 NDCs by Allowed Cost of the Top 200 NDCs (by Allowed Cost for Entire Population), Ordered by PMPM 
from January 1, 2018 to December 31, 2018 for the NH Medicare Population 
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Summary 
The high cost of medical and pharmaceutical treatment for diabetes nationally is well-documented. 
This report provides estimates for costs of treatment in NH commercial, Medicaid, and Medicare 
populations.  While the commercial data estimate has limitations and is likely a significant 
underestimate of the cost of diabetes in that population, the combined cost of diabetes across all three 
payers is more than $1.6 billion dollars according to this analysis. 
















Commercial (FY 2018) 6.57% $283.1M9 5.70% $102.9M $386.0M 
Medicaid (2019) 3.46% $134.1M 2.86% $15.4M $149.5M 
Medicare (2018) 20.98% $983.2M 16.96% $90.7M $1,073.8M 
 
  
                                                          
9 See notes about the estimate of costs in the commercial population in the “Limitations” section 
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Limitations 
There are several limitations to this analysis. As outlined in the Overview, the commercial medical data 
only represents about half of the actual commercial costs for treatment of diabetes in the commercial 
population. As noted in the Methodology in the Appendix, the analysis only includes members with 9 
or more months of eligibility; by not including members with less than 9 months of eligibility, the 
analysis results in an underestimate of the true cost of diabetes treatment in NH.  
The analysis only includes costs of diabetes that are captured in health care claims data and does not 
include an estimate of other costs associated with treatment of diabetes (e.g., time away from work, 
lost wages). 
This report does not include analysis of the racial and ethnic disparities of diabetes and the 
disproportionate cost of the disease borne by racial and ethnic minorities. The examination of health 
disparities is important; however, at this time, race and ethnicity fields are not available/reliable in the 
claims data and therefore not included in this report. IHPP will continually review the quality of the 
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Appendix A 
About the Data for the NH CHIS Commercial Population 
Member Selection Criteria for Analysis: 
• Age: 0-64 
• Residence: Members with policies that originate in NH; members can reside in NH or other states 
• Eligibility requirements: During a given 12-month measurement period (e.g. current period), a member 
is included in the analysis if the member was active for at least 9 months of the given 12-month 
measurement period (does not apply to members less than one year old). 
• Analytic Periods: Data are displayed by Previous Analytic Period and Current Analytic Period. The 
Current Analytic Period is based on the most recent 12 months of available claims data with the 
Previous Analytic Period being the 12 months prior. The Current Analytic Period for the NH Commercial 
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About the NH Medicaid Population 
Member Selection Criteria for Analysis: 
• Age: 0-64 
• Residence: Members with policies that originate in NH; members can reside in NH or other states. 
• Eligibility requirements: During a given 12-month measurement period (e.g. current period), a member 
is included in the analysis if the member was active for at least 9 months of the given 12-month 
measurement period (does not apply to members less than one year old). 
• Analytic Period: Data are displayed by Previous Analytic Period and Current Analytic Period. The Current 
Analytic Period is based on the most recent 12 months of available claims data with the Previous 
Analytic Period being the 12 months prior. The Current Analytic Period for the NH Medicaid population 
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About the NH Medicare Population 
Member Selection Criteria for Analysis: 
• Age: All ages 
• Residence: Members with policies that originate in NH. Members can reside in NH or other states to be 
included in the report suite, however for this report, the data has been filtered to only include members 
who lived within the one of NH’s seven Integrated Delivery Networks. 
• Eligibility requirements: During a given 12-month measurement period (e.g. current period), a member 
is included in the analysis if the member was active for at least 9 months of the given 12-month 
measurement period (does not apply to members less than one year old). 
• Analytic Period: Data are displayed by Previous Analytic Period and Current Analytic Period. The Current 
Analytic Period is based on the most recent 12 months of available claims data with the Previous 
Analytic Period being the 12 months prior. The Current Analytic Period for the NH Medicare population 
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Appendix B 
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NH Medicare Overall Pharmacy Costs: 
 
 
 
